NEW YORK – GenMark Diagnostics said Monday that it has been awarded a grant from the US Department of Health and Human Services (HHS) of up to $749,000 to develop and pursue US Food and Drug Administration Emergency Use Authorization (EUA) for a diagnostic panel that incorporates a new SARS-CoV-2 viral target into the company’s existing ePlex Respiratory Pathogen (RP) panel.